L- and M2- pyruvate kinase expression in renal cell carcinomas and their metastases

@article{Brinck2004LAM,
  title={L- and M2- pyruvate kinase expression in renal cell carcinomas and their metastases},
  author={Ulrich Brinck and G{\"o}sta Fischer and Erich Eigenbrodt and Matthias J. Oehmke and Sybille Mazurek},
  journal={Virchows Archiv},
  year={2004},
  volume={424},
  pages={177-185}
}
Using immunohistochemical and enzyme biochemical methods we investigated the expression of L- and M2-pyruvate kinase (PK) in normal renal tissue, renal cell carcinomas (RCCs; of clear cell, chromophilic cell and mixed cell type) and RCC metastases. L-PK was expressed in the proximal tubules of normal renal tissue and, to a variable extent, in 23/25 primary RCCs, in 1 RCC recurrence and in 10 RCC metastases. Staining intensity and percentage of stained tissue did not correlate with tumour grade… Expand
Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma
TLDR
It is recommended that the routine clinical use of TuM2-PK in metastatic RCC is not recommended at this point as it is not useful as a biological marker in localized RCC. Expand
The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.
TLDR
Since the marker sensitivity for detection of the early stages T1 and T2 was only 47% it is not suggested to use this marker for primary diagnosis of RCC, but its use as part of the confirmatory preoperative evaluation might be considered in view of its high PPV. Expand
Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
TLDR
Low sensitivity and specificity for stages T3 and T4 OSCC render the TuM2-PK test unsuitable as a tool for detecting OSCC, particularly in an early stage, and routine clinical and radiological follow-up is indispensable after treatment of OSCC. Expand
Tumour M2-pyruvate kinase: a gastrointestinal cancer marker
TLDR
Circulating tumour M2-pyruvate kinase is more commonly elevated in oesophageal, gastric and colorectal cancer patients than conventional tumour markers. Expand
Complete absence of M2-pyruvate kinase expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal neoplasia
TLDR
M2-PK is present only in benign non-ductal epithelium in normal pancreas and peri-tumoural tissue in chronic pancreatitis and normal Pancreas. Expand
Current Status of Tumor M2 Pyruvate Kinase (Tumor M2-PK) as a Biomarker of Gastrointestinal Malignancy
TLDR
The weight of evidence suggests that the test can be used as an adjunctive diagnostic test in conjunction with CA 19-9 and also that it may be a valuable biomarker of adverse prognosis. Expand
Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours.
  • S. Mazurek
  • Chemistry, Medicine
  • Ernst Schering Foundation symposium proceedings
  • 2007
TLDR
The quantification of Tumour M2-PK in EDTA plasma and stool is a tool for early detection of tumours and therapy control and is a meeting point for different oncogenes and metabolism. Expand
Current Status of Tumor M2 Pyruvate Kinase (Tumor M2-PK) as a Biomarker of Gastrointestinal Malignancy
Tumor pyruvate kinase M2 (tumor M2-PK) is a key enzyme in the altered metabolism of tumor tissue. In cancer, it is known to be present in high concentrations in malignant tissue, plasma and otherExpand
Tumor type M2 pyruvate kinase (TuM2‐PK) as a novel plasma tumor marker in melanoma
TLDR
Although the sensitivity and specificity to predict disease progression or death was higher for serum S100β compared to plasma TuM2‐PK, the combination of both markers improved the estimation of prognosis compared to that of serum S 100β alone. Expand
The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia–dysplasia–adenocarcinoma sequence in Barrett’s oesophagus
TLDR
Tumour M2-PK is not a specific marker of Barrett’s adenocarcinoma, but may be important as a marker of transformed and highly proliferating clones during progression along the metaplasia–dysplasia-adenocarc inoma sequence. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Carbohydrate metabolism in human renal clear cell carcinomas.
TLDR
It has been demonstrated that a series of characteristic changes occur in the carbohydrate metabolism of renal clear cell carcinomas: glycogen and glucose-6-phosphate levels increase, glycolysis is activated, and gluconeogenesis is reduced. Expand
Enolase isozymes in renal tubules and renal cell carcinoma.
TLDR
It is suggested that enolases are present mainly in the alpha alpha form in epithelial cells of proximal tubules, in the gamma gamma form in those of loops of Henle, and in the two forms and/or the alpha Gamma form in tumor cells of renal cell carcinoma. Expand
Differential diagnosis of histogenetically distinct human epithelial renal tumours with a monoclonal antibody against γ-glutamyltransferase
SummaryThe localization of membrane-bound γ-glutamyltransferase with monoclonal antibody (mAb) 138H11 proved to be of value for differential diagnosis of renal cancer, since it correlated with theExpand
Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens.
TLDR
Four highly reactive immunoglobulin G1 MABs generated following immunization of mice with either RCC homogenates, RCC cell lines, or fetal kidney homogenate expressed these antigens, showing various degrees of antigen restriction. Expand
Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells.
TLDR
The amount of the dimeric form in tumor cells closely correlates with the degree of malignancy and can be used for a nonspecific detection of tumors based on assays performed with patient's plasma. Expand
Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas.
TLDR
The PN-15 monoclonal antibody holds promise as a useful reagent in retrospective investigations of fixed, embedded cases of renal cell carcinomas and may also be of practical utility in diagnostic immunohistochemistry by helping to retrospectively define the primary site of metastatic clear cell tumors, especially when fresh frozen tissue from such tumors is not available. Expand
Cellular origin of rat renal oncocytoma.
  • E. Nogueira, P. Bannasch
  • Biology, Medicine
  • Laboratory investigation; a journal of technical methods and pathology
  • 1988
TLDR
Mitochondrial changes similar to those of fully developed oncocytes were recognized in principal and intercalated cells of these segments, indicating the involvement of these cell types in the genesis of the renal oncocytoma. Expand
The human chromophobe cell renal carcinoma: Its probable relation to intercalated cells of the collecting duct
TLDR
These findings strongly indicate that chromophobe renal cell carcinomas as well as oncocytomas of the kidney are histogenetically related to the two populations of intercalated cells of the collecting duct system. Expand
A Study of the Activities of Carbohydrate-Metabolizing Enzymes and the Levels of Carbohydrate Metabolites and Amino Acids in Normal Liver and in Hepatocellular Carcinoma
Primary hepatocellular carcinoma was induced by treatment with the initiator N’nitrosomorpholine followed by the promoting agents phenobarbital or Clofibrate. In those tumors, the activities ofExpand
Immunolocalization of prealbumin (transthyretin) in renal cell carcinoma
TLDR
It is concluded that prealbumin, which was absent in 14 adenocarcinomas from other organs, should be included in the panel of markers for differentiating metastatic adenOCarcinoma of renal origin from those of other primary tumours. Expand
...
1
2
3
4
...